For over 30 years, NYOH has been a leader in cancer research. Our patients have helped bring more than 100 FDA-approved cancer treatments to life by joining clinical trials. With the region’s largest cancer research program, we offer access to groundbreaking therapies—often before they’re available anywhere else.
Clinical trials are research studies involving volunteer participants who help evaluate new cancer treatments. These studies are essential to advancing cancer care, testing everything from the effectiveness of new drugs to innovative ways to manage side effects.
NYOH conducts Phase I through Phase IV clinical trials, covering all major solid tumors, blood cancers, and supportive care therapies. Our involvement in every phase of research ensures patients have access to the full spectrum of emerging treatment options.
At NYOH, you have access to cutting-edge cancer clinical trials without the need to travel to a large city. Our team is committed to bringing the latest, most promising treatments right here to your community so that you can stay close to home and with the people who support you. We're focused on advancing cancer care through safe, ethical research while making sure you receive the personalized, compassionate care you deserve.
More than 3,000 NYOH patients have participated in clinical trials over the past 20 years, helping to approve over 50 new cancer therapies. Their participation continues to shape the future of cancer treatment, offering hope to thousands more.
At New York Oncology Hematology (NYOH), we’re proud to be part of the breakthroughs that shape the future of cancer treatment. Many of the medications we now use in everyday cancer care were once tested in clinical trials right here at NYOH — giving our patients early access to cutting-edge therapies while helping bring life-saving treatments to the world.
Medications that attack fast-growing cancer cells directly.
|
Abraxane Alimta Camptosar Doxil Eloxatin |
Gemzar Halaven Hycamtin Ixempra Onivyde |
Taxotere Trodelvy Xeloda Yondelis |
Treatments that block cancer’s specific growth drivers, often with fewer side effects.
|
Afinitor Arimidex Aromasin Avastin Cyramza Erbitux Faslodex |
Herceptin Inlyta Iressa Kadcyla Nexavar Sutent Talzenna |
Tarceva Tykerb Vectibix Verzenio Votrient |
Treatments that block cancer’s specific growth drivers, often with fewer side effects.
|
Adcetris Bavencio Gazyva |
Keytruda Opdivo Provenge |
Rituxan Tecentriq |
Helping patients tolerate treatment and protect healthy cells.
|
Aranesp Neulasta |
Neupogen Zometa |
|
Medications used in leukemia, lymphoma, and related conditions.
|
Vidaza |
Sprycel |
Tasigna |
Hormone-targeting and immune-based treatments.
|
Erleada |
Provenge |
Our expert team of oncologists and research professionals leads clinical trials across every NYOH location. We partner with top pharmaceutical companies to bring the latest treatments to our community. Each trial is closely monitored for safety and effectiveness.
A Principal Investigator, a physician responsible for the design, conduct, and safety of the trial, oversees each study. The NYOH Research Oversight Committee, led by Dr. Lawrence Garbo (Chair) and Dr. Karen Tedesco (Vice Chair), ensures scientific integrity and regulatory compliance across all research activities.
To learn more about a study or to refer an eligible patient, please contact our research department.
Breast Studies
Hematology Studies
Breast Studies
Lung and Sarcoma Studies
Hematology Studies
GU Studies (Prostate, Bladder, Renal Cell)
General Cancer studies
Lung & Melanoma Studies
Hematology and Solid tumor studies
A clinical trial is a research study that involves people. It helps determine whether new cancer treatments are safe and effective after they’ve been tested in labs and on animals. Clinical trials are essential for improving how we prevent, detect, and treat cancer.
NYOH takes part in clinical research to:
Clinical trials are the foundation of modern cancer treatment. Every standard therapy used today was first studied in a trial. NYOH has helped gain FDA approval for over 100 cancer treatments. Clinical trials contribute to:
Only about 3% of adult cancer patients enroll in clinical trials. Increasing participation helps researchers find better treatments faster. NYOH offers the most comprehensive cancer clinical trial program in the region.
NYOH offers a variety of clinical trials, including:
A protocol is the detailed plan for a clinical trial. It outlines the purpose, treatment steps, number of participants, and how information is collected. All protocols are reviewed by qualified researchers and approved by an Institutional Review Board (IRB).
The IRB protects participants by ensuring:
©2025 New York Oncology Hematology. All rights reserved.